Product Name :
N-(2-Chloro-6-methylphenyl)-N’-4-pyridinylurea
Description:
N-[(1R)-4-[(Aminoiminomethyl)amino]-1-[[[(1R)-1-(4-hydroxyphenyl)ethyl]amino]carbonyl]butyl]-α-phenylbenzeneacetamide is an anticonvulsant agent with potential for the treatment of generalized tonic-clonic and partial seizures.
CAS:
97627-24-2
Molecular Weight:
261.71
Formula:
C13H12ClN3O
Chemical Name:
3-(2-chloro-6-methylphenyl)-1-(pyridin-4-yl)urea
Smiles :
CC1=CC=CC(Cl)=C1NC(=O)NC1C=CN=CC=1
InChiKey:
ZSBWDKCIIZYQIR-UHFFFAOYSA-N
InChi :
InChI=1S/C13H12ClN3O/c1-9-3-2-4-11(14)12(9)17-13(18)16-10-5-7-15-8-6-10/h2-8H,1H3,(H2,15,16,17,18)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
N-[(1R)-4-[(Aminoiminomethyl)amino]-1-[[[(1R)-1-(4-hydroxyphenyl)ethyl]amino]carbonyl]butyl]-α-phenylbenzeneacetamide is an anticonvulsant agent with potential for the treatment of generalized tonic-clonic and partial seizures.|Product information|CAS Number: 97627-24-2|Molecular Weight: 261.71|Formula: C13H12ClN3O|Chemical Name: 3-(2-chloro-6-methylphenyl)-1-(pyridin-4-yl)urea|Smiles: CC1=CC=CC(Cl)=C1NC(=O)NC1C=CN=CC=1|InChiKey: ZSBWDKCIIZYQIR-UHFFFAOYSA-N|InChi: InChI=1S/C13H12ClN3O/c1-9-3-2-4-11(14)12(9)17-13(18)16-10-5-7-15-8-6-10/h2-8H,1H3,(H2,15,16,17,18)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (477.63 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Crizanlizumab} MedChemExpress|{Crizanlizumab} Immunology/Inflammation|{Crizanlizumab} Technical Information|{Crizanlizumab} Description|{Crizanlizumab} supplier|{Crizanlizumab} Autophagy} |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|Compound shows anticonvulsant activity at 30 mg/kg in the initial tests with no signs of ataxia until 300 mg/kg.{{Anti-HA tag Rabbit mAb} site|{Anti-HA tag Rabbit mAb} Technical Information|{Anti-HA tag Rabbit mAb} Purity|{Anti-HA tag Rabbit mAb} custom synthesis|{Anti-HA tag Rabbit mAb} Epigenetics} The activity seen with 30 mg/kg 37 is still present 4 h postdose.PMID:23962101 Compound is effective against seizures induced by maximal electroshock but does not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that Compound would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound is selected for clinical trials.|Products are for research use only. Not for human use.|
